Charité - Universitätsmedizin Berlin
| Alemanha | Turquia | Áustria | |
| Tratamento complexo do neuroblastoma | de $90,000 | de $28,000 | de $180,000 |
A Bookimed não adiciona taxas extras aos preços de tratamento de Neuroblastoma. As tarifas vêm das listas oficiais de preços das clínicas. O pagamento é feito diretamente na clínica na chegada ao país.
A Bookimed está comprometida com sua segurança. Trabalha apenas com instituições que mantêm altos padrões internacionais no tratamento de Neuroblastoma e têm as licenças necessárias para atender pacientes internacionais em todo o mundo.
A Bookimed oferece assistência gratuita de especialistas. Um coordenador médico pessoal apoia antes, durante e após o tratamento, solucionando problemas. Nunca está sozinho em sua jornada de tratamento de Neuroblastoma.
O Prof. Jürgen Kiwit é um conceituado neurocirurgião alemão com mais de 25 anos de experiência, especializado em tumores cerebrais e da medula espinhal na Meoclinic Berlin.
Chefe do Departamento de Oncologia Pediátrica do prestigiado hospital Charité – o maior hospital universitário da Europa.
German pediatric oncology centers utilize standardized, multi-phase multimodal protocols coordinated by the German Society for Pediatric Oncology and Hematology. These include high-dose chemotherapy followed by autologous stem cell transplantation and anti-GD2 immunotherapy. Advanced centers like Charité Universitätsmedizin Berlin integrate 131I-mIBG therapy for refractory cases.
Bookimed Expert Insight: Germany maintains a highly organized infrastructure with 82 specialized clinics. Large university hospitals like Charité - Universitätsmedizin Berlin manage over 5,000 pediatric cases annually. This high volume allows departments led by experts like Dr. Angelika Eggert to refine complex CAR NK cell therapies. Such specialization ensures patients receive care that meets the strict German Cancer Society standards.
Patient Consensus: Patients note that high-risk care is concentrated in university hospitals with specialized pediatric teams. They emphasize the importance of monitoring side effects like hearing loss and neuropathy during intensive immunotherapy cycles.
Germany hosts several clinical trials for relapsed or high-risk neuroblastoma. Major academic centers participate in the BEACON2 and HR-NBL2 (SIOPEN) trials. These programs evaluate new drug combinations and immunotherapies. Patients often access these through university hospitals certified by the German Cancer Society.
Bookimed Expert Insight: While many countries offer standard care, Germany stands out for precision medicine registries like INFORM. Charité Berlin, an institution with 100 departments and over 4,000 doctors, serves as a major hub for these registries. This large patient volume often means faster accrual for early-phase drug trials compared to smaller regional centers.
Patient Consensus: Parents note that finding the right study depends on specific molecular testing. They emphasize having pathology and imaging results ready early to meet strict enrollment windows for relapsed disease protocols.